Volume 20, Number 4—April 2014
CME ACTIVITY - Research
Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009
Russell S. Barlow, Emilio E. DeBess
, Kevin L. Winthrop, Jodi A. Lapidus, Robert Vega, and Paul R. Cieslak
, Kevin L. Winthrop, Jodi A. Lapidus, Robert Vega, and Paul R. Cieslak
Table 4
Unadjusted associations of CIR of Salmonella isolates among 1,813 patients, by travel destination, Oregon, 2004–2009*
| Destination | No. patients | % CIR isolates | Odds ratio (95% CI) |
|---|---|---|---|
| None | 1,571 | 16.8 | Referent |
| Mexico | 119 | 9.2 | 0.5 (0.3–1.0) |
| Southeast Asia | 29 | 41.4 | 3.5 (1.7–7.4) |
| Europe | 25 | 16.0 | 0.9 (0.3–2.8) |
| East Asia | 17 | 35.3 | 2.7 (1.0–7.4) |
| Caribbean | 16 | 12.5 | 0.7 (0.2–3.1) |
| Central America† | 16 | 6.3 | 0.3 (0.1–2.5) |
| Africa | 10 | 20.0 | 1.2 (0.3–5.9) |
| Oceania | 5 | 20.0 | 1.2 (0.1–11.1) |
| Canada | 5 | 40.0 | 3.3 (0.5–19.8) |
| Any travel | 242 | 16.9 | 1.0 (0.7–1.4) |
*CIR, clinically important resistance to >1 of the following: ampicillin, ceftriaxone, ciprofloxacin, gentamicin, or trimethoprim/sulfamethoxazole. Boldface indicates statistical significance at p<0.05.
†Excludes Mexico.
Page created: March 18, 2014
Page updated: March 18, 2014
Page reviewed: March 18, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.